Due to dramatic tumor regression and the virtual absence of masses in the PRG4+ + regorafenib group, although some tissue samples were collected at the conclusion of the study, they were not sufficient in number for a deepen downstream molecular analysis. This evidence concerns the gene PRG4 and neoplasm.